Loading...
•
Jun 30, 2023
Compass Q2 2023 Earnings Report
Compass Therapeutics reported financial results for the second quarter of 2023.
Key Takeaways
Compass Therapeutics reported a net loss of $11.3 million for the second quarter of 2023, with R&D expenses increasing due to higher spending on CTX-009. The company's cash and marketable securities were $169 million as of June 30, 2023, providing a cash runway into 2026.
Phase 2 study of CTX-009 in patients with advanced CRC is on track, with initial data expected in the second half of the year.
Enrollment in Phase 2 study in patients with BTC has been slower than anticipated, and steps have been taken to address this.
Company is gearing toward filing a U.S. IND application for CTX-8371, a next-generation bispecific checkpoint axis blocker.
Cash and marketable securities were $169 million as of June 30, 2023, providing a cash runway into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...